Press Release – New York, New York – July 16, 2021 – Sichenzia Ross Ference LLP announced today that it represented Inmune Bio, Inc. (Nasdaq: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in a registered direct offering of common stock at a purchase price of $22.00 per share with two institutional investor. The gross proceeds from the offering were $40.0 million.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Marc Ross, Thomas Rose and Barrett DiPaolo.
SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents Dominari Securities, Revere Securities and Pacific Century Securities in $6 Million Initial Public Offering of BUUU Group Limited - August 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents RBW Capital Partners in $11.225 Million Private Placement of Digital Brands Group - August 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Laidlaw & Company and Craft Capital Management in $10 Million Initial Public Offering of Nasus Pharma - August 14, 2025
